Cata-Kor Enters Physical Retail with Target Launch, Bringing Its NAD+ Longevity Line to Stores Nationwide

By Newsfile

Miami, Florida--(Newsfile Corp. - October 14, 2026) - Cata-Kor, a U.S.-based nutraceutical company focused on science-informed longevity formulations, has launched two of its core products at Target stores nationwide on October 4. The launch marks the brand's first entry into physical retail and brings Cata-Kor NMN and Cata-Kor Liposomal NAD⁺ to the Vitamins & Supplements section across the U.S.

Cata-Kor

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8871/318203_catakortrgt.jpg

Both products are available in retail-specific 25-serving packs priced at $34.99, a format developed specifically for Target. Cata-Kor NMN delivers 500 mg of Beta-Nicotinamide Mononucleotide per serving, combined with Resveratrol, TMG, and Quercetin. Cata-Kor Liposomal NAD⁺ provides direct NAD⁺ support in a liposomal delivery format.

The two products represent complementary pathways within the same NAD+ portfolio — one built around a precursor-based mechanism, the other around direct delivery — giving Target guests a choice of formats within the brand's longevity-focused lineup.

"Launching at Target is a significant step for Cata-Kor as we move into physical retail," said Vlad Seuruk, CEO at Cata-Kor. "We built our presence online first. Taking that to Target means our products are now accessible to a much broader audience — people who want science-backed longevity options and find them on a shelf rather than searching for them online."

The Target launch follows a series of quality milestones for the brand. Cata-Kor NMN holds NSF certification under NSF/ANSI 173, confirming compliance with manufacturing quality, purity controls, and label accuracy. The company's NAD⁺ formulations have also undergone independent verification under the Alkemist Assured™ program.

Prior to its physical retail debut, Cata-Kor's NMN formula sold over 200,000 units on TikTok Shop.

About Cata-Kor

Cata-Kor is a U.S.-based nutraceutical company developing longevity formulations that support cellular health, vitality, and daily performance. Its portfolio is built around cellular energy mechanisms and healthy ageing pathways. Cata-Kor has a manufacturing facility in the United States and conducts all testing domestically, with a focus on transparency, quality, and science-informed development.

Media Contact

Roman Miroedov, PhD
Cata-Kor Press Office
press@catakor.com

Disclaimer

Statements made in this press release regarding Cata-Kor's dietary supplements have not been evaluated by the Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure, or prevent any disease. NSF/ANSI 173 certification verifies manufacturing quality, facility cGMP compliance, and label accuracy against contamination risks; it does not constitute an endorsement or evaluation of therapeutic claims by NSF or the FDA. Individuals should consult a healthcare professional before starting any dietary supplement regimen.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318203

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.